Predicted to enable cytokine activity; erythropoietin receptor binding activity; and protein kinase activator activity. Involved in several processes, including positive regulation of ERK1 and ERK2 cascade; positive regulation of activated T cell proliferation; and response to dexamethasone. Located in cell body and extracellular space. Used to study retinal detachment and visual epilepsy. Biomarker of cholangiocarcinoma; eye disease (multiple); transient cerebral ischemia; and vascular dementia. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); diabetic angiopathy; familial erythrocytosis 5; ischemia (multiple); and neurodegenerative disease (multiple). Orthologous to human EPO (erythropoietin); PARTICIPATES IN erythropoietin signaling pathway; hypoxia inducible factor pathway; cytokine mediated signaling pathway; INTERACTS WITH (+)-pilocarpine; 1H-indole; 2-methoxy-17beta-estradiol.
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] more ...
indole inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA], indole inhibits the reaction [cobaltous chloride results in increased expression of EPO protein]
2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of EPO protein], 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of EPO protein]
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP], EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP]
protocatechuic acid inhibits the reaction [methylmercuric chloride results in decreased expression of EPO protein], protocatechuic acid inhibits the reaction [Methylmercury Compounds results in decreased expression of EPO protein]
EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ...
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer], Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
bisphenol A inhibits the reaction [Cobalt results in increased expression of EPO mRNA], bisphenol A inhibits the reaction [HIF1A protein results in increased expression of EPO mRNA]
Cadmium inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EPO promoter]], Cadmium inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO mRNA], Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO protein]
[cobaltous chloride results in increased expression of and results in increased activity of HIF1A protein] which results in increased expression of EPO protein more ...
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA], Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]
Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA], Hydrogen Peroxide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]] more ...
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein], EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide]
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Hydrogen Peroxide], Hydrogen Peroxide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Indican inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA], Indican inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Ketoconazole inhibits the reaction [CYP3A4 protein promotes the reaction [Oxygen deficiency results in increased expression of EPO mRNA]], Ketoconazole inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ...
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein], 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in increased abundance of Nitrites]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]] more ...
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in decreased susceptibility to Levodopa], 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO results in increased phosphorylation of GSK3B protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of EPO protein], benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of EPO protein]
Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] more ...
Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein], tetramethylthiourea inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein]
resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein], resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein]
[peginterferon alfa-2b co-treated with Ribavirin] affects the expression of EPO protein, [Ribavirin co-treated with Interferons] results in increased expression of EPO protein
[salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein, [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein
EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ...
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein], Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA]
zinc chloride inhibits the reaction [cobaltous chloride results in increased expression of EPO protein], zinc chloride inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Impaired Synthesis of Erythropoietin, Glutamine Synthetase and Metallothionein in the Skin of NOD/SCID/gamma (c) (null) and Foxn1 nu/nu Mice with Misbalanced Production of MHC Class II Complex.
A comparative study of recombinant human basic fibroblast growth factor (bFGF) and erythropoietin (EPO) in prevention of skin flap ischemic necrosis in rats.
Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema.
Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor.
[Effects of umbilical cord blood monocytes transplantation on EPO protein and oligodendrocyte progenitors in neonatal rats with hypoxic-ischemic brain damage].
Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders.
The effect of erythropoietin on microcirculation perfusion and tissue bioenergetics of the small intestine in a hemorrhagic shock and resuscitation rat model.
Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(-)(3)(5) non-transgenic mouse model of Alzheimer's disease.
Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.
Erythropoietin neuroprotection is enhanced by direct cortical application following subdural blood evacuation in a rat model of acute subdural hematoma.
Investigation the efficacy of intra-articular prolotherapy with erythropoietin and dextrose and intra-articular pulsed radiofrequency on pain level reduction and range of motion improvement in primary osteoarthritis of knee.
Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span.
Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria?
Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema.
Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment.
